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http://dx.doi.org/10.1016/j.pedneo.2Intestinal failure is a chronic condition in which the intestinal tract has lost most of its func-
tion. Prognosis depends on the severity and underlying etiologies. Although many patients sur-
vive under parenteral nutrition support, they often suffer from fatal complications such as
progressive cholestasis and frequent sepsis. In addition, to decide the proper time to refer
selected patients to bowel transplantation remains difficult. A noninvasive biomarker devel-
oped to evaluate functional enterocyte mass and the extent of intestinal adaptation is plasma
citrulline level. It is shown that serum citrulline correlates with small bowel length, oral toler-
ance, and parenteral nutrition dependency. Recent evidence has revealed that the use of fish
oil containing lipid emulsions to substitute traditional soybean-based formula may reverse a
patient’s cholestasis and improve lipid profiles. A new method used to prevent catheter-
related bloodstream infection is ethanol lock therapy. With both antimicrobial and fibrinolytic
activities, studies have shown that ethanol locks can effectively decrease catheter infection
and replacement rate with no known resistance reported. As part of intestinal rehabilitation,
auxiliary surgeries such as longitudinal intestinal lengthening and tailoring, serial transverse
enteroplasty, and tapering enteroplasty can be beneficial for selected patients before bridging
to bowel transplantation. With the introduction of these new medical and surgical modalities,
patients with intestinal failure are having better outcomes than in the past.
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Intestinal failure (IF) is a chronic condition where the in-
testinal tract has lost most of its function, either resulting
from extensive bowel resection or diseases in which inad-
equate water and nutrient can be obtained unless paren-
teral nutrition (PN) is provided. The underlying causes of IF
vary in pediatric patients, with short bowel syndrome (SBS)
being the primary etiology.1 Long-term prognosis depends
on the etiologies, severity, and related complications.
Although utilization of PN has extended the life span of
patients, problems such as IF-associated cholestasis and
catheter-related infection remain to be resolved. Previ-
ously, the function of the remaining intestine could only be
assessed indirectly through oral tolerance, making it diffi-
cult to predict whether intestinal adaptation could be
achieved. Recently, with the introduction of noninvasive
clinical assessment such as plasma citrulline concentration,
newer formulation of PN, mainly omega-3 lipid emulsions,
more effective antiseptic strategy such as the ethanol lock
technique, and auxiliary surgical interventions namely
autologous gastrointestinal reconstruction (AGIR), patients
with IF can achieve a better prognosis than in the past.2. New assessment tool for patients with IF
The clinical assessment of pediatric patients with IF in-
cludes the following steps. Firstly, the underlying causes of
IF and the structure/function of the residual bowel are
identified. Diseases predisposing to IF can be classified into
three categories which consist of SBS resulting from
extensive bowel resection, motility disorders such as
Hirschsprung disease, and mucosal abnormalities (Table 1).
Determining the underlying etiologies may shed light on
whether IF would be “reversible” (i.e., intestinal adapta-
tion/autonomy may be achieved) or “permanent” (i.e.,
dependence on PN unless a bowel transplantation is per-
formed). For patients with suspected permanent IF, early
transplantation should be considered and arranged. The
residual bowel length and anatomy can be evaluated by
detailed history taking, previous surgical records, radio-
graphic examination, GI series, and intestinal transit time.Table 1 Diseases predisposing to pediatric intestinal
failure.
Short bowel syndrome
d Necrotizing enterocolitis (most common)
d Malrotation with midgut volvulus
d Gastroschisis
d Intestinal atresia
d Inflammatory bowel disease
Motility disorders
d Long segment Hirschsprung disease
d Intestinal pseudo-obstruction
Mucosal abnormalities
d Microvillous inclusion disease
d Tufting enteropathy
d Autoimmune enteropathyUsually clinical features, underlying physiological changes,
and even prognosis can be predicted by the remnant GI
regions.2,3 Sondheimer et al4 reviewed 44 neonates who
had small bowel resection and were dependent on PN for at
least 3 months. They concluded that the residual small
bowel length after the initial surgery and the percentage of
daily energy intake through enteral route at 12 weeks’
adjusted age were significantly related to PN dependence.
A new noninvasive biomarker recently used to evaluate
functional enterocyte mass is plasma citrulline concentra-
tion. Citrulline is a nonprotein amino acid produced almost
exclusively by enterocytes; thus, patients with SBS and
mucosal injury of the bowel may have lower levels of
plasma citrulline. A study by Vecino Lopez et al5 measured
the serum citrulline level in 57 pediatric patients with IF
and found that those who were totally or partially depen-
dent on PN had significantly lower plasma citrulline
levels compared with those who were weaned from PN
(7.1  4.1, 15.8  8.9 vs. 20.6  7.5, 28.8  10.1,
p < 0.001). Fitzgibbons et al6 concluded that plasma
citrulline >15 mmol/L could predict PN wean off. Rhoads
et al7 showed that serum citrulline >19 mmol/L could pre-
dict the development of enteral tolerance. Other studies
have also correlated serum citrulline level with small bowel
length, bowel adaptation, and PN dependence in pediatric
patients with SBS.8e10 As citrulline is excreted by the kid-
ney, patients with renal insufficiency may not have reduced
citrulline concentration. Although there is as yet no
consistent cut-off value, these studies show promising re-
sults and further research is warranted.
Secondly, the nutritional status of patients, including
fluid and electrolytes, trace elements, vitamins, tri-
glycerides, and essential fatty acids (FAs), should be thor-
oughly assessed. In addition, individualized supplement of
each nutrient is very important. Thirdly, any complications
related to PN and underlying diseases need to be evaluated
and managed throughout the whole care. After these initial
evaluations, physicians could provide suitable and individ-
ualized treatment programs according to the current status
of a patient.3. New modalities in caring for IF patients
Nearly all patients diagnosed with IF rely on long-term PN
to maintain their lives. However, intestinal failure-
associated liver disease (IFALD) and catheter-related
bloodstream infection (CRBSI) are the two main complica-
tions associated with long-term PN use.11 Therefore, how to
prevent and manage these two problems has become a key
issue in daily practice.
The prevalence of IFALD varies between studies. It is
estimated that 40e60% of children, and up to 85% of neo-
nates receiving prolonged periods of PN will develop
IFALD.12e14 Previous reports have shown that IFALD is
directly related to the survival and outcome of a patient.15,16
The clinical scenarios range from steatohepatitis, chole-
stasis, and hepatic fibrosis to end-stage liver disease.
Generally, neonatal patients often suffer from aggressive,
cholestatic liver disease, whereas adult patients only have
steatosis or steatohepatitis.17 Although it is sometimes
called parenteral nutrition-associated liver disease (PNALD),
428 C.-F. Chan, T.-C. Wuthe underlying mechanisms of IFALD are multifactorial. One
of the most important risk factors is the use of omega-6 FAs
containing lipid emulsions, which are the precursors of many
proinflammatory cytokines.18e21 The use of omega-3 FA-
based lipid emulsions will theoretically decrease inflamma-
tion. Recently, many centers have reported their clinical
experiences with the use of fish oil (an omega-3 FA) to sub-
stitute traditional lipid emulsions in pediatric cholestatic
patients. Puder et al22 performed an open-labeled trial of
fish oil-based lipid emulsion (Omegaven) in 42 infants with
SBS and PNALD (defined by direct bilirubin >34.2 mmol/L)
while on soybean oil-based lipid emulsions. The results were
compared with those who kept using the soybean oil-based
formula. They concluded that the infants who changed to
Omegaven experienced reversal of cholestasis six times
faster than the control group. In addition, mortality and liver
transplantation rateswere also significantly lower during the
study period. Later in 2011, the same group published
another report and revealed that the use of fish oil-based
lipid emulsions not only improved PN-cholestasis but also
had a positive effect on lipid profiles (increase in omega-3
FAs, decrease in triglyceride, very low density lipoprotein,
and omega-6 FAs). No essential fatty acid deficiency was
found in their patients.23 In 2010, Goulet et al24 performed a
randomized, double-blind study to evaluate the effective-
ness of SMOFlipid (a mixed lipid emulsion containing 15% fish
oil and an appropriate amount of a-tocopherol, which
contributed to the anti-inflammatory and antioxidative ef-
fects, respectively). Twenty-eight children on home PN with
cholestasis were enrolled in their study. Compared with the
control group using soybean oil emulsions, the childrenTable 2 Use of fish oil-based lipid emulsions in pediatric chole
Authors Patients’ characteristics Study design
Puder et al22 Infants with SBS &
cholestasis (D-bil
> 34.2 mmol/L);
Study group (n Z 42);
Control group (n Z 49)
Open-labeled;
Study group: Ome
1 g/kg/d;
Control group: Int
1e4 g/kg/d
Le et al23 Children with SBS- & PN-
associated cholestasis
(D-bil  34.2 mmol/L);
79 children enrolled
Bilirubin, lipid, &
profile before & a
use of Omegaven
(1 g/kg/d) were
compared
Goulet et al24 Children on home PN;
Study group (n Z 15);
Control group (n Z 13)
Randomized, doub
blind study;
Study group: SMO
up to 2 g/kg/d;
Control group: Int
up to 2 g/kg/d
Premkumar et al25 Infants with PN-
associated cholestasis
(D-bil  34.2 mmol/L);
57 infants enrolled
Prospective
observational stud
Conjugated bilirub
TG, & LFT monito
after Omegaven
(1 g/kg/d) use
D-bil Z direct bilirubin; FAs Z fatty acids; LFT Z liver function t
TG Z triglyceride; VLDL Z very low density lipoprotein.receiving SMOFlipid had a decreased total bilirubin level and
increased omega-3 FAs and a-tocopherol. Despite some
concern about the possibility of essential FA deficiency,
inadequate growth, and coagulopathy, current evidence
shows that short-term use of these omega-3 FA-based lipid
emulsions may reverse a patient’s cholestasis and improve
lipid profiles. Nevertheless, the beneficial effects of these
omega-3 FAsmay be due to the lower dosage, relatively short
duration, and mixed components of the formula. More
studies are needed to further clarify the safety, side effects,
and optimal dosage for patients when long-term use is
considered. Recent studies discussing omega-3 lipid emul-
sions are highlighted in Table 2.22e25
Another complication which is frequently encountered
in IF patient is CRBSI, which seems inevitable when pro-
longed PN is provided. It is also an important risk factor
contributing to IFALD. The incidence of CRBSI in children
with IF is estimated to be between 0.9 infections per 1000
catheter days and 11 infections per 1000 catheter days.26
Guidelines published by the Centers for Disease Control
and Prevention recommends education of health care pro-
viders, maximal sterile barrier precautions, and the use of
>0.5% chlorhexidine for skin antisepsis to prevent CRBSI.
Prophylatic antibiotic locks are only suggested in patients
with a history of multiple infections despite optimal aseptic
technique, with concerns about the emergence of resistant
organisms.27
Because of the difficulties in vascular assessment in
pediatric patients, practical guidelines from the Infectious
Diseases Society of America recommends antibiotic lock
therapy plus systemic antibiotics for catheter salvage instatic patients.
Results Comments
gaven
ralipid
Use of Omegaven
reversed cholestasis;
Decreased mortality &
liver transplantation
rates
Results may be due to
different dosage
between two groups;
Approximately 25% of
patients received PN for
less than 3 wk
FA
fter
Use of Omegaven
decreased bilirubin,
TG, VLDL, & omega-6
FAs;
Increased omega-3 FAs
Results may be due to
lower lipid dosage
le-
Flipid
ralipid
Use of SMOFlipid
decreased total
bilirubin;
Increased omega-3 FAs
& a-tocopherol
Results may be due to
mixed components of
SMOFlipid;
Short duration of PN use
y;
in,
red
Cholestasis resolved in
w80% patients
Results may be due to
lower lipid dosage
est; PN Z parenteral nutrition; SBS Z short bowel syndrome;
Recent advances in pediatric intestinal failure 429clinically stable children with CRBSI.28 A meta-analysis
containing 16 randomized controlled trials showed a small
overall benefit in using the antibiotic lock technique to
prevent CRBSI.29 Onder et al30 retrospectively reviewed five
children with intestinal transplantation and short gut syn-
drome. Tobramycin-tissue plasminogen activator for 4
hours per day for 6 weeks was used to prevent catheter-
related bacteremia. The results showed a significant
decrease of catheter-related bacteremia and related hos-
pitalization during the study period.
A new method recently used to prevent CRBSI is ethanol
lock therapy (ELT). With both antimicrobial and fibrinolytic
activities, ethanol can denature protein and hence destroy
the biofilms. Jones et al31 retrospectively reviewed 23 PN-
dependent children with IF. Ethanol (70%) was instilled
three times per week, with a minimum dwell time of 4
hours. The central venous catheter (CVC) infection rate
decreased from 9.9 per 1000 catheter days to 2.1 per 1000
catheter days during ELT. Wales et al32 also reported their
experiences in ELT. The CVCs of 10 children with IF were
instilled with 70% ethanol for 4 hours daily. The CVC
infection rate decreased from 10.2 per 1000 catheter days
to 0.9 per 1000 catheter days, and replacements dropped
from 5.6 per 1000 days to 0.3 per 1000 days after initiating
ELT. Of the 10 children, two stopped ELT due to catheter
thrombosis. A meta-analysis published in 2012 showed that,
compared with heparin locks, ELT was more effective in
preventing CRBSI, with the infection and replacement rates
decreased by 81% and 72%, respectively.33 Of note is that
ethanol is not compatible with heparin and will precipitate
if mixed with heparinized saline. Ethanol may also weaken
the silicon tube and it is not recommended for use in
polyurethane catheters.34 Despite the rare adverse events
and different protocols, current studies show that ELT has a
robust effect in preventing CRBSI, with the advantages of
no known resistance and ready availability. Randomized
controlled trials are needed to further support the efficacy
and the safety of this strategy in the future.4. Auxiliary surgical approaches to IF
Besides adequate nutrition support and aggressive infection
control, some patients with IF need auxiliary surgical in-
terventions to achieve intestinal autonomy and resolve
complications before bridging to transplantation. Common
surgeries that are currently available include longitudinal
intestinal lengthening and tailoring (LILT), serial transverse
enteroplasty (STEP), and tapering enteroplasty.35,36
Almond et al37 reported their experiences of eight chil-
dren with IF who underwent AGIR (3 LILT, 2 STEP, and 3
tapering enteroplasty) because of adaptation failure. The
mean gut length increased from 51 cm to 73 cm, and the
postoperative incidence of sepsis and peak bilirubin levels
significantly decreased. They concluded that reducing the
bowel diameter through the surgeries above might be
beneficial for selected patients. Reports from centers
excelling in intestinal rehabilitation programs further
approved the role of AGIR, especially in patients with bowel
dysmotility and dilatation.38e41 A recent report from the
International Serial Transverse Enteroplasty Data Registry
showed that among the 78 patients requiring PN, 37 (47%)achieved enteral autonomy after the first STEP. The two
independent risk factors for progressing to transplantation
or death were higher direct bilirubin level and shorter pre-
STEP bowel length.42 Overall, surgical management should
not be viewed as the last resort; instead, it is part of the
intestinal rehabilitation.
5. Conclusion
IF is a catastrophe to both patients and their families, and
prevention is the most important strategy. The manage-
ment of pediatric patients with IF is very complicated. Only
with a multidisciplinary approach including both medical
and surgical expertise can survival and overall outcome be
improved. Current evidence shows that plasma citrulline
level, which is correlated with functional enterocyte mass
and bowel length, can be used to predict enteral adapta-
tion and PN dependence in patients with SBS. Shifting the
conventional soy-based formula to low-dose fish oil con-
taining hepato-protective PN may reverse a patient’s
cholestasis and improve lipid profiles. Besides antibiotic
and heparin lock therapy, ELT is another method to reduce
CRBSI, with limited side effects such as thrombosis. As part
of intestinal rehabilitation, AGIR can be beneficial for
selected patients before bridging to intestinal trans-
plantation. More randomized controlled trials are needed in
the future to further clarify the roles of these new
modalities.
Conflicts of interest
The authors have no conflicts of interest relevant to this
article.References
1. De Marco G, Barabino A, Gambarara M, Diamanti A,
Martelossi S, Guarino A. Network approach to the child with
primary intestinal failure. J Pediatr Gastroenterol Nutr 2006;
43:S61e7.
2. Amin SC, Pappas C, Lyengar H, Maheshwari A. Short bowel
syndrome in the NICU. Clin Perinatol 2013;40:53e68.
3. Soden JS. Clinical assessment of the child with intestinal fail-
ure. Semin Pediatr Surg 2010;19:10e9.
4. Sondheimer JM, Cadnapaphornchai M, Sontag M, Zerbe GO.
Predicting the duration of dependence on parenteral nutrition
after neonatal intestinal resection. J Pediatr 1998;132:80e4.
5. Vecino Lo´pez R, Andre´s Moreno AM, Ramos Boluda E, Martinez-
Ojinaga Nodal E, Hernanz Macı´as A, Prieto Bozano G, et al.
Plasma citrulline concentration as a biomarker of intestinal
function in short bowel syndrome and in intestinal transplant.
An Pediatr (Barc) 2013;79:218e23. [Article in Spanish].
6. Fitzgibbons S, Ching YA, Valim C, Zhou J, Iglesias J, Duggan C,
et al. Relationship between serum citrulline levels and pro-
gression to parenteral nutrition independence in children with
short bowel syndrome. J Pediatr Surg 2009;44:928e32.
7. Rhoads JM, Plunkett E, Galanko J, Lichtman S, Taylor L,
Maynor A, et al. Serum citrulline levels correlate with enteral
tolerance and bowel length in infants with short bowel syn-
drome. J Pediatr 2005;146:542e7.
8. Diamanti A, Panetta F, Gandullia P, Morini F, Noto C, Torre G,
et al. Plasma citrulline as marker of bowel adaptation in
430 C.-F. Chan, T.-C. Wuchildren with short bowel syndrome. Langenbecks Arch Surg
2011;396:1041e6.
9. Bailly-Botuha C, Colomb V, Thioulouse E, Berthe MC,
Garcette K, Dubern B, et al. Plasma citrulline concentration
reflects enterocytes mass in children with short bowel syn-
drome. Pediatr Res 2009;65:559e63.
10. Jianfeng G, Weiming Z, Ning L, Fangnan L, Li T, Nan L, et al.
Serum citrulline is a simple quantitative marker for small in-
testinal enterocytes mass and absorption function in short
bowel patients. J Surg Res 2005;127:177e82.
11. Diamanti A, Basso MS, Castro M, Calce A, Pietrobattista A,
Gambarara M. Prevalence of life-threatening complications in
pediatric patients affected by intestinal failure. Transplant
Proc 2007;39:1632e3.
12. Ching YA, Gura K, Modi B, Jaksic T. Pediatric intestinal failure:
nutrition, pharmacologic, and surgical approaches. Nutr Clin
Pract 2007;22:653e63.
13. Btaiche IF, Khalidi N. Parenteral nutrition-associated liver
complications in children. Pharmacotherapy 2002;22:
188e211.
14. Kelly DA. Liver complications of pediatric parenteral nutrition e
epidemiology. Nutrition 1998;14:153e7.
15. Willis TC, Carter BA, Rogers SP, Hawthorne KM, Hicks PD,
Abrams SA. High rates of mortality and morbidity occur in in-
fants with parenteral nutrition-associated cholestasis. JPEN J
Parenter Enteral Nutr 2010;34:32e7.
16. Quiro´s-Tejeira RE, Ament ME, Reyen L, Herzog F,
Merjanian M, Olivares-Serrano N, et al. Long-term parenteral
nutritional support and intestinal adaptation in children with
short bowel syndrome: a 25-year experience. J Pediatr 2004;
145:157e63.
17. Kumpf VJ. Parenteral nutrition-associated liver disease in adult
and pediatric patients. Nutr Clin Pract 2006;21:279e90.
18. Goulet O, Joly F, Corriol O, Colomb-Jung V. Some new insights
in intestinal failure-associated liver disease. Curr Opin Organ
Transplant 2009;14:256e61.
19. Carter BA, Shulman RJ. Mechanisms of disease: update on the
molecular etiology and fundamentals of parenteral nutrition
associated cholestasis. Nat Clin Pract Gastroenterol Hepatol
2007;4:277e87.
20. Gabe SM. Lipids and liver dysfunction in patients receiving
parenteral nutrition. Curr Opin Clin Nutr Metab Care 2013;16:
150e5.
21. Nandivada P, Cowan E, Carlson SJ, Chang M, Gura KM, Puder M.
Mechanisms for the effects of fish oil lipid emulsions in the
management of parenteral nutrition-associated liver disease.
Prostaglandins Leukot Essent Fatty Acids 2013;89:153e8.
22. Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM,
et al. Parenteral fish oil improves outcomes in patients with
parenteral nutrition-associated liver injury. Ann Surg 2009;
250:395e402.
23. Le HD, de Meijer VE, Robinson EM, Zurakowski D, Potemkin AK,
Arsenault DA, et al. Parenteral fish-oil-based lipid emulsion
improves fatty acid profiles and lipids in parenteral nutrition-
dependent children. Am J Clin Nutr 2011;94:749e58.
24. Goulet O, Ante´bi H, Wolf C, Talbotec C, Alcindor LG, Corriol O,
et al. A new intravenous fat emulsion containing soybean oil,
medium-chain triglycerides, olive oil, and fish oil: a single-
center, double-blind randomized study on efficacy and safety
in pediatric patients receiving home parenteral nutrition. JPEN
J Parenter Enteral Nutr 2012;34:485e95.
25. Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA.
High rates of resolution of cholestasis in parenteral nutrition-
associated liver disease with fish oil-based lipid emulsion
monotherapy. J Pediatr 2013;162:793e8.26. Piper HG, Wales PW. Prevention of catheter-related blood
stream infections in children with intestinal failure. Curr Opin
Gastroenterol 2013;29:1e6.
27. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J,
Heard SO, et al. Guidelines for the prevention of intravascular
catheter-related infections. Clin Infect Dis 2011;59:e162e93.
28. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP,
et al. Clinical practice guidelines for the diagnosis and man-
agement of intravascular catheter-related infection: 2009 up-
date by the Infectious Diseases Society of America. Clin Infect
Dis 2009;49:1e45.
29. Snaterse M, Ru¨ger W, Scholte Op Reimer WJ, Lucas C. Antibi-
otic-based catheter lock solutions for prevention of catheter-
related bloodstream infection: a systematic review of rando-
mised controlled trials. J Hosp Infect 2010;75:1e11.
30. Onder AM, Kato T, Simon N, Rivera-Hernandez M, Chandar J,
Montane B, et al. Prevention of catheter-related bacteremia in
pediatric intestinal transplantation/short gut syndrome chil-
dren with long-term central venous catheters. Pediatr Trans-
plant 2007;11:87e93.
31. Jones BA, Hull MA, Richardson DS, Zurakowski D, Gura K,
Fitzgibbons SC, et al. Efficacy of ethanol locks in reducing
central venous catheter infections in pediatric patients with
intestinal failure. J Pediatr Surg 2010;45:1287e93.
32. Wales PW, Kosar C, Carricato M, de Silva N, Lang K, Avitzur Y.
Ethanol lock therapy to reduce the incidence of catheter-
related bloodstream infections in home parenteral nutrition
patients with intestinal failure: preliminary experience. J
Pediatr Surg 2011;46:951e6.
33. Oliveira C, Nasr A, Brindle M, Wales PW. Ethanol locks to pre-
vent catheter-related bloodstream infections in parenteral
nutrition: a meta-analysis. Pediatrics 2012;129:318e29.
34. Crnich CJ, Halfmann JA, Crone WC, Maki DG. The effects of
prolonged ethanol exposure on the mechanical properties of
polyurethane and silicone catheters used for intravascular
access. Infect Control Hosp Epidemiol 2005;26:708e14.
35. Bianchi A. Intestinal loop lengthening e a technique for
increasing small intestinal length. J Pediatr Surg 1980;15:
145e51.
36. Kim HB, Fauza D, Garza J, Oh JT, Nurko S, Jaksic T. Serial
transverse enteroplasty (STEP): a novel bowel lengthening
procedure. J Pediatr Surg 2003;38:425e9.
37. Almond SL, Haveliwala Z, Khalil B, Morabito A. Autologous in-
testinal reconstructive surgery to reduce bowel dilatation im-
proves intestinal adaptation in children with short bowel
syndrome. J Pediatr Gastroenterol Nutr 2013;56:631e4.
38. Fusaro F, Hermans D, Reding R. Autologous gastrointestinal
reconstructive surgery: complement or alternative to intestinal
transplantation. Curr Opin Organ Transplant 2013;18:286e90.
39. Rege AS, Sudan DL. Autologous gastrointestinal reconstruction:
review of the optimal nontransplant surgical options for adults
and children with short bowel syndrome. Nutr Clin Pract 2013;
28:65e74.
40. Khalil BA, Ba’ath ME, Aziz A, Forsythe L, Gozzini S, Murphy F,
et al. Intestinal rehabilitation and bowel reconstructive sur-
gery: improved outcomes in children with short bowel syn-
drome. J Pediatr Gastroenterol Nutr 2012;54:505e9.
41. Ba’ath ME, Almond S, King B, Bianchi A, Khalil BA, Morabito A.
Short bowel syndrome: a practical pathway leading to suc-
cessful enteral autonomy. World J Surg 2012;36:1044e8.
42. Jones BA, Hull MA, Potanos KM, Zurakowski D, Fitzgibbons SC,
Ching YA, et al. Report of 111 consecutive patients enrolled in
the International Serial Transverse Enteroplasty (STEP) Data
Registry: a retrospective observational study. J Am Coll Surg
2013;216:438e46.
